Immunopharmacology: Foundations and Cytokine Pharmacology

Correct Answer

C — Tofacitinib

Rationale

Tofacitinib preferentially inhibits Janus kinase 1 and Janus kinase 3 and was the first Janus kinase inhibitor to receive approval, in 2012. Baricitinib preferentially inhibits Janus kinase 1 and Janus kinase 2. Upadacitinib is a highly selective Janus kinase 1 inhibitor with approximately 60-fold selectivity over Janus kinase 2. Abrocitinib is also a selective Janus kinase 1 inhibitor approved for atopic dermatitis.

Correct Answer

B — Apremilast

Rationale

Apremilast is classified as a phosphodiesterase 4 inhibitor. It is approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's disease. Tofacitinib and upadacitinib are Janus kinase inhibitors. Deucravacitinib is an allosteric inhibitor of tyrosine kinase 2 that targets the regulatory pseudokinase domain rather than a phosphodiesterase enzyme.

Correct Answer

A — Ozanimod

Rationale

Ozanimod is classified as a selective sphingosine-1-phosphate receptor 1 and receptor 5 modulator. It is approved for relapsing multiple sclerosis and moderate-to-severe ulcerative colitis. Apremilast is a phosphodiesterase 4 inhibitor. Tofacitinib is a Janus kinase 1 and Janus kinase 3 inhibitor. Vedolizumab is a monoclonal antibody targeting the alpha-4/beta-7 integrin and is administered parenterally, not orally.

Correct Answer

D — Deucravacitinib

Rationale

Deucravacitinib is classified as an allosteric tyrosine kinase 2 inhibitor. Unlike conventional Janus kinase inhibitors that compete with adenosine triphosphate at the catalytic kinase domain (JH1), deucravacitinib binds the regulatory pseudokinase domain (JH2) of tyrosine kinase 2, stabilizing it in an autoinhibited conformation. This allosteric mechanism confers greater than 2,000-fold selectivity for tyrosine kinase 2 over Janus kinase 1, Janus kinase 2, and Janus kinase 3. Tofacitinib and upadacitinib are competitive adenosine triphosphate-binding Janus kinase inhibitors. Apremilast inhibits phosphodiesterase 4.

Correct Answer

B — Upadacitinib

Rationale

Upadacitinib is a selective Janus kinase 1 inhibitor with the broadest indication set of any approved Janus kinase inhibitor. It is the only Janus kinase inhibitor approved for Crohn's disease and ulcerative colitis in addition to rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis. This broad gastrointestinal approval reflects both its Janus kinase 1 selectivity and the clinical trial program that supported these indications. Tofacitinib preferentially inhibits Janus kinase 1 and Janus kinase 3 and is not approved for Crohn's disease. Baricitinib preferentially inhibits Janus kinase 1 and Janus kinase 2 and is approved for rheumatoid arthritis and alopecia areata but not for inflammatory bowel disease. Deucravacitinib is an allosteric tyrosine kinase 2 inhibitor, not a Janus kinase inhibitor, and is approved only for plaque psoriasis.

Correct Answer

C — Vedolizumab

Rationale

Vedolizumab is a humanized monoclonal antibody classified by its target: the alpha-4/beta-7 integrin heterodimer on lymphocyte surfaces. By blocking this integrin, vedolizumab prevents lymphocyte binding to mucosal addressin cell adhesion molecule 1 on gut endothelium, selectively blocking lymphocyte trafficking into the gut lamina propria. Ustekinumab targets the p40 subunit shared by interleukin-12 and interleukin-23. Risankizumab targets the p19 subunit of interleukin-23 selectively. Ozanimod is a sphingosine-1-phosphate receptor modulator and is an oral small molecule, not a monoclonal antibody.

Correct Answer

C — Patients aged 65 or older, smokers, or those with established cardiovascular disease, prior malignancy, or prior venous thromboembolism

Rationale

The class-wide Janus kinase inhibitor black box warning — applied to tofacitinib, baricitinib, upadacitinib, and abrocitinib following the ORAL Surveillance trial findings — identifies specific higher-risk patient groups in whom Janus kinase inhibitors should be avoided when alternative treatments are available: patients aged 65 or older, current or past smokers, and those with established cardiovascular disease, prior malignancy, or prior venous thromboembolism. The warning covers serious infections, malignancy, major adverse cardiovascular events, thrombosis, and mortality. Janus kinase inhibitors are also restricted in rheumatic indications to use after tumor necrosis factor inhibitor failure. Renal impairment, elevated liver enzymes, and other autoimmune diagnoses are not listed as the primary populations driving the avoidance recommendation.

Correct Answer

C — Phosphodiesterase 4 inhibition raises cyclic adenosine monophosphate levels, producing anti-inflammatory cytokine suppression without broad lymphocyte depletion or immunosuppression

Rationale

Phosphodiesterase 4 is the predominant phosphodiesterase in immune cells; its inhibition by apremilast prevents breakdown of cyclic adenosine monophosphate to inactive 5-adenosine monophosphate. Elevated cyclic adenosine monophosphate activates protein kinase A, which suppresses transcription of pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin-17, interleukin-23, and interferon-gamma while increasing the anti-inflammatory cytokine interleukin-10. This mechanism produces targeted cytokine suppression without depleting lymphocytes, inhibiting T-cell proliferation broadly, or impairing pathogen surveillance. The result is anti-inflammatory efficacy in psoriasis and psoriatic arthritis without the serious infection, malignancy, or cardiovascular risk signals that characterize biologic agents and Janus kinase inhibitors.

Correct Answer

B — Cardiac monitoring for at least 6 hours after the first dose; required in patients with pre-existing conduction abnormalities or concurrent use of heart rate-lowering medications because of the risk of bradycardia and atrioventricular block

Rationale

Ozanimod activates sphingosine-1-phosphate receptor 1 on cardiac conduction tissue, which can transiently slow sinoatrial node firing and atrioventricular conduction, producing bradycardia and atrioventricular block with the first dose. First-dose cardiac monitoring for at least six hours is required for patients who have pre-existing cardiac conduction abnormalities, sick sinus syndrome, or are taking medications that lower heart rate, such as beta-blockers or non-dihydropyridine calcium channel blockers. A gradual one-week dose titration schedule reduces the magnitude of this first-dose effect. Ozanimod does not cause acute hepatotoxicity, hypertensive urgency, or rapid complete blood count changes at first dose.

Correct Answer

B — Deucravacitinib's allosteric binding to the tyrosine kinase 2 pseudokinase domain confers greater than 2,000-fold selectivity for tyrosine kinase 2 over Janus kinase 1, Janus kinase 2, and Janus kinase 3, avoiding the off-target effects that drive the black box warning

Rationale

The class-wide Janus kinase inhibitor black box warning is based on the ORAL Surveillance trial findings with tofacitinib, a Janus kinase 1/Janus kinase 3 inhibitor, and was extended to all agents inhibiting Janus kinase 1, Janus kinase 2, or Janus kinase 3 as a class effect. Deucravacitinib works through an entirely different mechanism: it binds the regulatory pseudokinase domain (JH2) of tyrosine kinase 2 rather than competing with adenosine triphosphate at the catalytic domain. The JH2 domains of the four Janus kinase family members differ substantially in structure, providing greater than 2,000-fold selectivity for tyrosine kinase 2. Because deucravacitinib does not meaningfully inhibit Janus kinase 1, Janus kinase 2, or Janus kinase 3 at clinical doses, it does not carry the Janus kinase inhibitor class warnings and does not require prior tumor necrosis factor inhibitor failure before use.

Correct Answer

D — Vedolizumab

Rationale

Vedolizumab is the preferred biologic in patients with prior malignancy, recurrent serious infections, or advanced age because its mechanism of action — blocking the alpha-4/beta-7 integrin to selectively prevent lymphocyte trafficking into the intestinal wall — does not impair systemic immune surveillance. Unlike tumor necrosis factor inhibitors, Janus kinase inhibitors, or agents that broadly suppress lymphocyte function, vedolizumab leaves systemic immunity intact, avoiding the malignancy reactivation risk and infection susceptibility associated with systemic immunosuppression. Tofacitinib carries a class-wide black box warning for malignancy and is contraindicated in patients with prior cancer when alternatives exist. Adalimumab and ustekinumab are appropriate for Crohn's disease but both carry systemic immunosuppression that is less favorable than vedolizumab in this high-risk patient.

Correct Answer

A — Baricitinib; inhibits Janus kinase 1 and Janus kinase 2

Rationale

Baricitinib was the first systemic therapy approved for alopecia areata, a distinction earned through the BRAVE-AA1 and BRAVE-AA2 trials that demonstrated meaningful scalp hair regrowth in patients with severe disease. Baricitinib preferentially inhibits Janus kinase 1 and Janus kinase 2. Alopecia areata is an autoimmune condition driven by cytotoxic T-cell attack on hair follicles, and Janus kinase inhibition suppresses the inflammatory cytokine signaling responsible for this follicular immune attack. Tofacitinib inhibits Janus kinase 1 and Janus kinase 3 and is used off-label in alopecia areata but is not the approved agent. Upadacitinib and deucravacitinib are not approved for alopecia areata.

Correct Answer

D — Ozanimod active metabolites have serotonergic activity, and monoamine oxidase inhibition blocks serotonin catabolism, risking serotonin syndrome

Rationale

Ozanimod is metabolized to active metabolites that possess serotonergic activity independent of their sphingosine-1-phosphate receptor modulating properties. When monoamine oxidase inhibitors are coadministered, the normal enzymatic breakdown of serotonin is blocked, allowing serotonin to accumulate to potentially toxic levels. The combination can cause serotonin syndrome, which presents with hyperthermia, agitation, myoclonus, clonus, and autonomic instability. Coadministration of ozanimod with monoamine oxidase inhibitors is therefore contraindicated. A washout period of at least 14 days after stopping a monoamine oxidase inhibitor is required before initiating ozanimod.

Correct Answer

B — Abrocitinib inhibits Janus kinase 1, blocking interleukin-31 signaling on sensory neurons that is the primary driver of itch in atopic dermatitis

Rationale

Interleukin-31 is a key pruritogenic cytokine in atopic dermatitis that signals through a receptor complex requiring Janus kinase 1 on sensory neurons in the skin. This direct neuronal signaling pathway explains why interleukin-31-driven itch can be relieved within days of Janus kinase 1 inhibition — the neuronal signal is interrupted rapidly, before significant reduction in skin inflammation is needed. Abrocitinib, as a selective Janus kinase 1 inhibitor, produces this rapid itch relief while also addressing the broader Th2-mediated inflammation of atopic dermatitis. The speed of itch relief distinguishes Janus kinase inhibitors from biologics such as dupilumab, which typically require several weeks for full anti-pruritic effect.

Correct Answer

B — Screening for latent tuberculosis, hepatitis B, and baseline complete blood count, and updated vaccinations including recombinant zoster vaccine before starting therapy

Rationale

Despite upadacitinib's high Janus kinase 1 selectivity and its approval for Crohn's disease, it carries the same class-wide black box warning as all other approved Janus kinase inhibitors, and mandatory pre-treatment screening applies. Required steps before initiating any Janus kinase inhibitor include screening for latent tuberculosis with a tuberculin skin test or interferon-gamma release assay, hepatitis B surface antigen and core antibody testing, and a baseline complete blood count. Live vaccine administration is contraindicated once therapy starts, so the recombinant zoster vaccine and any other needed live vaccines should be completed before initiation. Janus kinase 1 selectivity reduces — but does not eliminate — the hematological and infectious risks of the class; it does not exempt the agent from screening requirements or the black box warning.

Correct Answer

B — Do not initiate ozanimod while phenelzine is active; the combination is contraindicated because ozanimod metabolites have serotonergic activity and monoamine oxidase inhibition blocks serotonin catabolism, risking serotonin syndrome

Rationale

Ozanimod is metabolized to active metabolites that possess serotonergic activity. When a monoamine oxidase inhibitor such as phenelzine is coadministered, enzymatic breakdown of serotonin is blocked, allowing serotonin to accumulate to levels capable of causing serotonin syndrome — a potentially life-threatening toxidrome characterized by hyperthermia, agitation, myoclonus, clonus, and autonomic instability. Coadministration of ozanimod with any monoamine oxidase inhibitor is therefore contraindicated. Before ozanimod can be initiated, phenelzine must be discontinued and a washout period of at least 14 days must elapse to allow sufficient monoamine oxidase enzyme recovery. Dose reduction of phenelzine does not safely resolve the interaction. The relevant adverse effect is serotonin toxicity, not bradycardia; bradycardia is a first-dose cardiac effect mediated through sphingosine-1-phosphate receptor 1 on conduction tissue and is unrelated to monoamine oxidase inhibitor use.

Correct Answer

D — Baricitinib; Janus kinase 1 and Janus kinase 2 inhibition suppressing the inflammatory cytokine signaling that drives autoimmune follicular attack, with meaningful scalp hair coverage expected by 36 weeks in clinical trials

Rationale

Baricitinib is the first and only systemic therapy with regulatory approval specifically for alopecia areata, approved on the basis of the BRAVE-AA1 and BRAVE-AA2 trials. As a Janus kinase 1 and Janus kinase 2 inhibitor, it suppresses the inflammatory cytokine signaling — including interferon-gamma and related cytokines — responsible for the autoimmune attack on hair follicles. In trials, meaningful scalp hair coverage (SALT score of 20 or less) was achieved in approximately 35 to 40% of patients at 36 weeks. Apremilast is not approved for alopecia areata. Dupilumab is approved for atopic dermatitis and asthma, not alopecia areata. Deucravacitinib is approved only for plaque psoriasis and is not indicated in alopecia areata.

Correct Answer

C — Deucravacitinib, because its allosteric tyrosine kinase 2 selectivity produces no clinically meaningful Janus kinase 1, Janus kinase 2, or Janus kinase 3 inhibition and does not carry the Janus kinase inhibitor black box warning

Rationale

The class-wide Janus kinase inhibitor black box warning covers all approved agents that inhibit Janus kinase 1, Janus kinase 2, or Janus kinase 3 — including tofacitinib, baricitinib, upadacitinib, and abrocitinib — and recommends avoiding them in patients with established cardiovascular disease, prior myocardial infarction, or age 65 or older when alternatives exist. Deucravacitinib works through an allosteric mechanism at the tyrosine kinase 2 pseudokinase domain (JH2), providing greater than 2,000-fold selectivity for tyrosine kinase 2 over the other Janus kinase family members. Because it does not meaningfully inhibit Janus kinase 1, Janus kinase 2, or Janus kinase 3, it does not carry the Janus kinase inhibitor black box warning and is an appropriate oral alternative for psoriasis in high cardiovascular risk patients. It does not require prior tumor necrosis factor inhibitor failure.